Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALGN
ALGN logo

ALGN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
189.450
Open
188.950
VWAP
186.18
Vol
88.57K
Mkt Cap
13.49B
Low
184.180
Amount
16.49M
EV/EBITDA(TTM)
13.40
Total Shares
71.62M
EV
12.15B
EV/OCF(TTM)
17.58
P/S(TTM)
3.25
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
Show More

Events Timeline

(ET)
2026-06-30
20:30:00
Align Technology Responds to EU Investigation
select
2026-06-30
12:30:00
Align Technology Shares Drop 4% Amid EU Antitrust Investigation
select
link
2026-06-30
09:30:00
European Commission Opens Antitrust Investigation into Align Technology
select
link
2026-06-18 (ET)
2026-06-18
21:30:00
Align Technology Chairman C. Raymond Larkin, Jr. to Retire in 2026
select
2026-05-22 (ET)
2026-05-22
16:20:00
Align Technology Plans New Manufacturing Facility in Hyderabad, India
select
2026-05-22
14:50:00
Align Technology to Invest ₹1,800 Crore in New Plant in India
select
link
2026-05-01 (ET)
2026-05-01
06:00:00
Align Technology Plans to Repurchase $200M of Stock
select

News

NASDAQ.COM
9.5
07-03NASDAQ.COM
Illumina Positioned for Strong Growth Ahead
  • Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has sharpened its strategy on the core sequencing business, aiming for high-single-digit revenue growth and double-digit to teens EPS growth by 2027, demonstrating a commitment to sustainable growth.
  • NovaSeq X Deployments: In Q1 2026, Illumina placed over 80 NovaSeq X units, exceeding expectations and reflecting strong clinical demand, with plans to maintain an average deployment of 50 to 60 units quarterly, further solidifying its market position.
  • Clinical Demand Driving Growth: Clinical sequencing consumables demand grew 20% year-over-year in Q1 2026, indicating broader adoption of NGS testing, with expectations that most clinical volumes will transition to the NovaSeq X platform by the end of 2026.
  • Challenges in China Market: Despite strong overall performance, Illumina's revenues in Greater China fell 27.8% year-over-year, facing regulatory and geopolitical uncertainties that limit growth potential in the region and may impact overall performance.
Newsfilter
9.5
07-01Newsfilter
Align Technology to Report Q2 2026 Financial Results on July 29
  • Earnings Release Schedule: Align Technology will report its Q2 2026 financial results on July 29 after market close, with results available at 4:00 PM ET (1:00 PM PT), reflecting the company's commitment to transparency and investor communication.
  • Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 PM ET (1:30 PM PT), with pre-registration available on the company website, indicating a desire for close engagement with investors and real-time feedback.
  • Digital Transformation Progress: The Invisalign system has treated approximately 22.8 million patients, showcasing Align's leadership in digital dentistry while providing efficient digital workflows for around 299,500 doctor customers, further solidifying its market share.
  • Market Opportunity: Align's products and services tap into a global consumer market opportunity of 600 million, highlighting the company's extensive influence and growth potential in the digital orthodontics and restorative dentistry sectors.
NASDAQ.COM
7.0
07-01NASDAQ.COM
Align Technology Responds to EU Antitrust Investigation
  • Antitrust Investigation Launched: The European Commission initiated a formal antitrust investigation against Align Technology on June 30, 2026, based on a competitor's complaint, aiming to determine potential violations of EU competition laws that could impact the company's market position.
  • Focus of Investigation: The inquiry centers on two measures taken by Align since 2017, including the refusal to approve competing state-of-the-art scanners for digital scan submissions and the rejection of scans from other intra-oral scanners, despite compliance with industry-standard files, which may limit market competition.
  • Company's Response: Align Technology believes the investigation is purely procedural and reiterated the performance capabilities of its proprietary iTero intra-oral scanner; while not directly addressing the allegations of intentional exclusivity, it emphasized that the iTero platform can be used for aligners other than Invisalign.
  • Market Performance Overview: Align's stock has traded between $122.00 and $208.31 over the past year, closing at $168.66 on Tuesday with a decline of 2.75%, and in pre-market trading, shares are down slightly to $168.52, reflecting market concerns regarding the investigation.
seekingalpha
7.0
07-01seekingalpha
Align Technology Pushes Back Against EU Investigation
  • Market Success Defense: Align Technology (ALGN) asserts that its success in the teeth-straightening market is driven by innovation rather than unfair practices, emphasizing that the quality, innovation, and customer experience of its products and services form the foundation of its market advantage.
  • Antitrust Investigation Initiated: The European Commission has launched an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition, which Align strongly disputes.
  • Procedural Step Clarification: Align Technology clarifies that the Commission's investigation is a procedural step aimed at gathering information and does not imply a conclusion on the merits of the case or an accusation of wrongdoing, stressing its commitment to fully cooperate with the inquiry.
  • Executive Changes Context: Amid the EU antitrust probe, Align Technology is also undergoing a board shakeup, with Kevin Conroy set to succeed retiring Chairman C. Raymond Larkin, which may influence the company's strategic direction moving forward.
Newsfilter
7.0
07-01Newsfilter
Align Technology Responds to EU Investigation
  • Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
  • iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
  • Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
  • Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
seekingalpha
7.0
06-30seekingalpha
European Commission Launches Antitrust Investigation into Align Technology
  • Antitrust Investigation Launched: The European Commission has initiated an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition and harming its reputation.
  • Concerns Over Market Dominance: The Commission is worried that Align Technology may have unfairly leveraged its market-leading Invisalign clear aligners by effectively forcing dental professionals to purchase the iTero scanner to order Invisalign for their patients, which could lead to market inequities.
  • Restrictive Interoperability Strategy: The investigation focuses on Align's so-called 'restrictive interoperability strategy,' which includes refusal to approve competing state-of-the-art scanners and refusal to accept dental professionals' submissions of scans, potentially hindering industry innovation.
  • Uncertain Financial Outlook: Although Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion and reaffirms a 3%-4% revenue growth for 2026, the antitrust investigation may negatively impact its future performance.
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
Wall Street analysts forecast ALGN stock price to rise
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
169.00
Averages
198.70
High
220.00
Current: 0.000
sliders
Low
169.00
Averages
198.70
High
220.00
Leerink
Outperform
maintain
$230
AI Analysis
2026-06-30
Reason
Leerink
Price Target
$230
AI Analysis
2026-06-30
maintain
Outperform
Reason
Leerink reiterated an Outperform rating and $230 price target on Align Technology, saying the firm's understanding from precedent EU antitrust cases is that it could take 2-4 years between formal opening of an antitrust probe and resolution, with the low end representing a scenario where the company complies and doffers commitments around scanner/case submission interoperability and the high end representing a potential infringement decision. Given this marks the first formal EU antitrust case in the medical device space, resolution from the commission could potentially take longer than usual, the analyst tells investors in a research note. As a result, the firm believes the case presents headline risk but will likely not have much of a fundamental impact on Align.
Leerink
Michael Cherny
Outperform
maintain
2026-05-27
Reason
Leerink
Michael Cherny
Price Target
2026-05-27
maintain
Outperform
Reason
Leerink analyst Michael Cherny says that the Align Technology "Tech Talk" wasn't intended to unveil anything drastically new or different but helped provide additional details on the various platform advantages and growth levers that help support long-term growth. Whether it is the conversion opportunity for teens, the Advanced Restorative Treatment potential with lab partnerships, the peer-to-peer expansions, the further evolution of ClinCheck, or the planned scaling of direct fab, the firm believes the company has a lot of positive drivers in various areas of revenue and margin opportunities. The overall messaging continued to be one of positive company advancements for the medium/long term. Leerink sees numerous ways for Align to drive multi-year upside and doesn't see that as factored into the current stock price. The firm maintains an Outperform rating on the stock.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ALGN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Align Technology Inc (ALGN.O) is 16.23, compared to its 5-year average forward P/E of 29.77. For a more detailed relative valuation and DCF analysis to assess Align Technology Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
29.77
Current PE
16.23
Overvalued PE
44.82
Undervalued PE
14.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.17
Current EV/EBITDA
14.75
Overvalued EV/EBITDA
29.50
Undervalued EV/EBITDA
10.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.41
Current PS
3.09
Overvalued PS
8.22
Undervalued PS
2.60

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

ok give me a strong swing for three months
Intellectia · 18 candidates
Region: USPrice: $10.00 - $1000.00Market Cap Category: large, megaRelative Vol: >= 1.50Beta: ModerateRisk, HighRiskList Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: $-10.00 - $30.00Quarter Price Change Pct: $0.00 - $60.00Is Optionable: TrueOption Iv Rank: 20 - 80One Month Rise Prob: >= 60One Month Predict Return: >= 5.0%Macd: positive, bullish
Ticker
Name
Market Cap$
top bottom
CAVA logo
CAVA
CAVA Group Inc
11.20B
PL logo
PL
Planet Labs PBC
13.16B
FLEX logo
FLEX
Flex Ltd
31.30B
STRL logo
STRL
Sterling Infrastructure Inc
14.51B
MTSI logo
MTSI
MACOM Technology Solutions Holdings Inc
21.43B
TT logo
TT
Trane Technologies PLC
106.04B
que me recomiendas para invertir hoy
Intellectia · 46 candidates
Analyst Consensus: Strong Buy, Moderate BuyIs Index Component: GSPC, NDX, DJIOne Month Rise Prob: >= 60One Month Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ALGN logo
ALGN
Align Technology Inc
12.66B
BWA logo
BWA
Borgwarner Inc
11.33B
MTCH logo
MTCH
Match Group Inc
7.61B
MCO logo
MCO
Moody's Corp
79.68B
IEX logo
IEX
IDEX Corp
14.68B
GDDY logo
GDDY
GoDaddy Inc
10.78B
top 10 recommended day trader for today
Intellectia · 48 candidates
Price: $5.00 - $200.00Relative Vol: >= 1.10List Exchange: XNYS, XNAS, XASEIs Index Component: GSPC, NDXMin5 Price Change Pct: >= $0.10Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ACN logo
ACN
Accenture PLC
118.30B
WRB logo
WRB
W R Berkley Corp
24.24B
TEAM logo
TEAM
Atlassian Corp
17.18B
BSX logo
BSX
Boston Scientific Corp
102.80B
NOW logo
NOW
ServiceNow Inc
103.98B
AIG logo
AIG
American International Group Inc
39.14B
which stocks have high short float
Intellectia · 65 candidates
Market Cap: >= 5.00BRegion: USPrice: >= $10.00Short Ratio: MoreThan30PctList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
WSO logo
WSO
Watsco Inc
15.96B
WYNN logo
WYNN
Wynn Resorts Ltd
10.60B
NEU logo
NEU
NewMarket Corp
6.03B
PRAX logo
PRAX
Praxis Precision Medicines Inc
8.65B
MEDP logo
MEDP
Medpace Holdings Inc
13.36B
KRYS logo
KRYS
Krystal Biotech Inc
7.42B
good swing trades today
Intellectia · 104 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: $5.00 - $20.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
FMC logo
FMC
FMC Corp
2.00B
TER logo
TER
Teradyne Inc
47.75B
GLW logo
GLW
Corning Inc
103.50B
CE logo
CE
Celanese Corp
6.39B
CAT logo
CAT
Caterpillar Inc
347.41B
ON logo
ON
ON Semiconductor Corp
26.55B
what should I invest in right now?
Intellectia · 87 candidates
Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: $20.00 - $60.00Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
420.10B
FCX logo
FCX
Freeport-McMoRan Inc
90.84B
GLW logo
GLW
Corning Inc
103.50B
TPR logo
TPR
Tapestry Inc
31.01B
STX logo
STX
Seagate Technology Holdings PLC
86.41B
LRCX logo
LRCX
Lam Research Corp
282.98B
what stocks will
Intellectia · 3459 candidates
Market Cap: >= 100.00MPrice: $1.00 - $200.00Monthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
KELYB logo
KELYB
Kelly Services Inc
510.65M
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
PAHC logo
PAHC
Phibro Animal Health Corp
1.66B
FORM logo
FORM
FormFactor Inc
5.43B
LBRX logo
LBRX
LB Pharmaceuticals Inc
526.22M
ENSG logo
ENSG
Ensign Group Inc
10.05B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B

Whales Holding ALGN

C
Caxton Associates (USA) LLC
Holding
ALGN
+32.15%
3M Return
B
Bellevue Asset Management AG
Holding
ALGN
+18.31%
3M Return
D
Disciplined Growth Investors, Inc.
Holding
ALGN
+15.47%
3M Return
J
Jacobs Levy Equity Management Inc
Holding
ALGN
+12.72%
3M Return
R
Ruane, Cunniff & Goldfarb L.P.
Holding
ALGN
+12.11%
3M Return
T
The Investment House LLC
Holding
ALGN
+11.65%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Align Technology Inc (ALGN) stock price today?

The current price of ALGN is 184.92 USD — it has decreased -1.84

What is Align Technology Inc (ALGN)'s business?

Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.

What is the price predicton of ALGN Stock?

Wall Street analysts forecast ALGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGN is198.70 USD with a low forecast of 169.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Align Technology Inc (ALGN)'s revenue for the last quarter?

Align Technology Inc revenue for the last quarter amounts to 1.04B USD, increased 6.21

What is Align Technology Inc (ALGN)'s earnings per share (EPS) for the last quarter?

Align Technology Inc. EPS for the last quarter amounts to 1.57 USD, increased 23.62

How many employees does Align Technology Inc (ALGN). have?

Align Technology Inc (ALGN) has 20290 emplpoyees as of July 07 2026.

What is Align Technology Inc (ALGN) market cap?

Today ALGN has the market capitalization of 13.49B USD.